Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated Qutenza treatment for peripheral neuropathic pain
NL-OMON34497Phase 4Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of capsaicin in Peripheral neuropathic pain, postherpetic neuralgia (PHN), HIV-associated neuropathy and 1 more, sponsored by Astellas Pharma. Primary endpoints: Adverse events, Serious adverse events and 3 more. Started Feb 2011; status: active, not recruiting.
02
Drugs
capsaicin
03
Conditions
Peripheral neuropathic painpostherpetic neuralgia (PHN)HIV-associated neuropathycryptogenic small fiber neuropathy (iSFN)
Beyond the preview
Go deeper on NL-OMON34497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34497.